September 26, 2024

TerraTrust nominated for the DQS Sustainability Award 2024 in the “Sustainable Innovation” category

TerraTrust nominated for the DQS Sustainability Award 2024 in the “Sustainable Innovation” category

We are pleased to announce significant news: the first sustainable and biodegradable pregnancy test in Europe developed by Zamann Pharma Support, under the Terra Trust house brand, has been nominated for the prestigious DQS Sustainability Award 2024 in the “Sustainable Innovation” category. This nomination is a confirmation of their tireless commitment to environmental protection and sustainable innovation.

Every year, the DQS Sustainability Awards recognize companies that are pioneers in sustainability. It is one of the most important awards in the field of sustainability, recognizing companies, regardless of their size, for their innovative approaches to promoting environmental protection and social responsibility. This nomination is not only a recognition for Terra Trust, but underscores how necessary sustainable solutions have become in all areas of life, including the healthcare industry.

For Terra Trust, this nomination symbolizes much more than just a recognition of their technical innovation. It highlights the growing importance of environmental protection in a sector traditionally characterized by plastic waste and environmentally harmful disposables. Their product represents a new generation of pregnancy tests that protect the environment without compromising on quality or accuracy.

More Information in German / Original News:

Our latest News

discover more
Diaper Recycling: Progress Even Among the Market Leader

Diaper Recycling: Progress Even Among the Market Leader

Used diapers account for a very large portion of our waste, and to date, no economically viable recycling process has been established. In the Encycling project, the NMI team led by Dr. Anne Zeck and Dr. Simon Straß developed an enzymatic process that was successfully applied to diapers from various manufacturers. Further research was needed […]

From microscopy to AI: Andreas von Deimling shaped modern brain tumor diagnostics in Heidelberg

From microscopy to AI: Andreas von Deimling shaped modern brain tumor diagnostics in Heidelberg

After almost 20 years, Professor Dr. Andreas von Deimling has handed over leadership of Neuropathology at Heidelberg University Hospital to Professor Dr. Dr. Felix Sahm. When Andreas von Deimling was appointed W3 Professor of Neuropathology in 2007, Heidelberg Faculty of Medicine at Heidelberg University, together with the German Cancer Research Center (DKFZ), pursued a strategic […]

Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany

Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany

Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Paris and Frankfurt, October 19, 2026. Sanofi today broke ground on a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany. The new facility will bring a new generation of insulin production to one of Sanofi’s largest integrated research and manufacturing sites, […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp